GlaxoSmithKline plc (MX:GSKN) — Stock Price

MX$890.54 MXN
▼ -3.41% today

GlaxoSmithKline plc (MX:GSKN) is currently trading at MX$890.54 MXN, down 3.41% today. Over the past 52 weeks, shares have ranged between MX$710.00 and MX$1041.90. This page tracks GlaxoSmithKline plc's live share price on the MX exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GSKN stock market capitalisation.

GlaxoSmithKline plc (GSKN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks GlaxoSmithKline plc's daily closing share price and trading volume on the MX exchange over the past year, giving a clear view of recent price momentum and liquidity.

GlaxoSmithKline plc Income Statement — Revenue, Profit & Earnings by Year

GlaxoSmithKline plc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue MX$31.38 Billion MX$30.33 Billion MX$29.32 Billion MX$34.11 Billion MX$34.10 Billion
Cost of Revenue MX$9.05 Billion MX$8.56 Billion MX$9.55 Billion MX$11.60 Billion MX$11.70 Billion
Gross Profit MX$22.33 Billion MX$21.76 Billion MX$19.77 Billion MX$22.51 Billion MX$22.39 Billion
Research & Development MX$6.40 Billion MX$6.22 Billion MX$5.49 Billion MX$5.28 Billion MX$5.10 Billion
SG&A MX$11.02 Billion MX$9.38 Billion MX$8.37 Billion MX$10.97 Billion MX$11.46 Billion
Total Operating Expenses MX$25.83 Billion MX$22.98 Billion MX$22.89 Billion MX$27.91 Billion MX$26.32 Billion
Operating Income MX$5.54 Billion MX$7.34 Billion MX$6.43 Billion MX$6.20 Billion MX$7.78 Billion
EBITDA — — MX$8.80 Billion MX$8.75 Billion MX$10.18 Billion
EBIT — — MX$7.32 Billion MX$5.63 Billion MX$6.05 Billion
Interest Expense MX$640.00 Million MX$725.00 Million MX$879.00 Million MX$777.00 Million MX$856.00 Million
Income Before Tax MX$3.48 Billion MX$6.06 Billion MX$5.63 Billion MX$5.44 Billion MX$6.97 Billion
Income Tax Expense — — MX$707.00 Million MX$83.00 Million MX$67.00 Million
Net Income MX$2.58 Billion MX$4.93 Billion MX$14.96 Billion MX$4.38 Billion MX$5.75 Billion

GlaxoSmithKline plc Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes GlaxoSmithKline plc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets MX$59.46 Billion MX$59.01 Billion MX$60.15 Billion MX$79.10 Billion MX$80.43 Billion
Total Current Assets MX$17.00 Billion MX$18.64 Billion MX$20.77 Billion MX$18.67 Billion MX$20.25 Billion
Cash & Equivalents — — — — —
Short-term Investments MX$21.00 Million MX$2.25 Billion MX$4.15 Billion MX$61.00 Million MX$78.00 Million
Net Receivables MX$5.56 Billion MX$5.91 Billion MX$5.45 Billion MX$6.25 Billion MX$5.55 Billion
Inventory MX$5.67 Billion MX$5.50 Billion MX$5.15 Billion MX$5.78 Billion MX$6.00 Billion
Property, Plant & Equipment — — MX$9.62 Billion MX$10.67 Billion MX$11.01 Billion
Goodwill MX$6.98 Billion MX$6.81 Billion MX$7.05 Billion MX$10.55 Billion MX$10.60 Billion
Total Liabilities MX$46.38 Billion MX$46.21 Billion MX$50.05 Billion MX$57.76 Billion MX$59.62 Billion
Total Current Liabilities MX$21.70 Billion MX$21.07 Billion MX$22.81 Billion MX$23.67 Billion MX$22.15 Billion
Long-term Debt MX$13.70 Billion MX$14.15 Billion MX$16.19 Billion MX$19.76 Billion MX$22.54 Billion
Net Debt MX$12.19 Billion MX$14.06 Billion MX$16.46 Billion MX$19.08 Billion MX$19.94 Billion
Total Stockholder Equity MX$13.67 Billion MX$13.35 Billion MX$10.60 Billion MX$15.05 Billion MX$14.59 Billion
Retained Earnings MX$7.80 Billion MX$7.24 Billion MX$4.79 Billion MX$8.75 Billion MX$7.29 Billion

GlaxoSmithKline plc Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how GlaxoSmithKline plc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow MX$6.55 Billion MX$5.48 Billion MX$7.40 Billion MX$7.95 Billion MX$8.44 Billion
Capital Expenditures MX$2.98 Billion MX$2.31 Billion MX$1.14 Billion MX$950.00 Million MX$989.00 Million
Free Cash Flow MX$3.57 Billion MX$3.17 Billion MX$5.14 Billion MX$5.02 Billion MX$6.20 Billion
Investing Cash Flow — — MX$-8.77 Billion MX$-1.78 Billion MX$2.16 Billion
Financing Cash Flow — — MX$823.00 Million MX$-7.59 Billion MX$-10.13 Billion
Dividends Paid MX$-2.44 Billion MX$2.33 Billion MX$3.47 Billion MX$4.00 Billion MX$3.98 Billion
Stock-Based Compensation MX$344.00 Million MX$307.00 Million MX$346.00 Million MX$367.00 Million MX$381.00 Million
Depreciation MX$2.55 Billion MX$1.53 Billion MX$2.15 Billion MX$2.12 Billion MX$2.05 Billion
Change in Cash MX$599.00 Million MX$-313.00 Million MX$-394.00 Million MX$-1.44 Billion MX$431.00 Million

GlaxoSmithKline plc Earnings History — EPS Actual vs. Analyst Estimates

Track GlaxoSmithKline plc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 29, 2026 — 1.16 —
Feb 04, 2026 7.58 0.62 +1122.16%
Oct 29, 2025 24.65 1.26 +1856.48%
Jul 30, 2025 18.30 1.11 +1548.68%
Apr 30, 2025 20.18 — —
Feb 05, 2025 5.14 — —
Oct 30, 2024 -0.70 — —
Jul 31, 2024 12.39 — —